Free Consultation
CASE STUDY
Medical Device for Oxygen Therapy
We supported OxyNov in developing FreeO2, a medical device that allows hospitals to administer oxygen therapy more safely and accurately to their patients.
OxyNov FreeO2: an innovative medical device that pushes the limits of oxygen therapy
Company
Industry
Medtech
Sector
Respiratory Health
Product Type
Physical Device with Digital Interface
Expertise
- Electronic Engineering, Embedded Software Development, Human Factors Engineering, Industrial Design, Innovation Strategy, Mechanical Engineering, Quality Assurance, Software Development, UX & UI Design
Oxygen therapy treats millions of patients every day
Oxygen therapy is a respiratory support treatment that provides oxygen to millions of patients daily.
OxyNov is a young Canadian company that exclusively markets medical devices in this field. It has designed FreeO2, a device that automates and improves oxygen therapy administration by making it more efficient, safe, and comfortable for patients, especially for those with chronic obstructive pulmonary disease (COPD).
CLEIO has been asked to accelerate the development of this innovative medical device.
How CLEIO accelerated the development of an innovative medical device
OxyNov developed the algorithm for automation but needed assistance moving their innovation beyond a prototype used for research. CLEIO has designed a device ready for market and much easier to install and use.
All our teams were mobilized on this mandate to realize the full potential of the invention. We provide OxyNov with strategic advice and support in user experience design, engineering, embedded software development, interface design, and industrial design.
Meeting essential user needs
OxyNov conducted several formative studies to ensure that FreeO2’s functionality, technology, and experience would meet the exact needs of the different user groups. Based on the recommendations and results of the studies, our designers created the device’s user interface. They improved it with evaluations before finalizing the user experience and the visual appearance.
Meeting essential user needs
OxyNov conducted several formative studies to ensure that FreeO2’s functionality, technology, and experience would meet the exact needs of the different user groups. Based on the recommendations and results of the studies, our designers created the device’s user interface. They improved it with evaluations before finalizing the user experience and the visual appearance.
Designing a product that is consistent with the imagined one
Our industrial designers came into play early in the project. They ensured that the product looked like the one OxyNov had in mind regarding functionality, technology, and user experience. They determined the overall device size and the location of the external connections.
At CLEIO, our teams work together early to avoid having to do design alterations later in the manufacturing stage.
Putting patient safety first with software controls
CLEIO’s embedded software engineers have designed an application that puts patient safety first by implementing numerous controls and redundancies. For example, the FreeO2 can continuously adjust the oxygen flow sent to the patient according to the various parameters the physician has defined.
Prototyping for tests and certifications
We used the first version of the prototype for testing, validation, and certification. We have modified the second prototype to obtain CE and CSA certification in collaboration with our quality assurance team.
An ongoing collaboration with OxyNov
Our close collaboration with OxyNov allowed us to develop the best possible product. Our teams remained permanently in contact throughout the project to validate the technological choices and the user needs.
We set up regular meetings and direct communication channels. Each team shared its feedback and approval quickly.
A medical innovation ready for launch in 18 months
OxyNov’s FreeO2 was ready for launch in 18 months with a user-friendly design and CE and CSA certification.
Today, this innovative medical device is receiving widespread interest from hospitals and is undergoing the Food Drug Administration (FDA) approval process for commercialization in the United States.
“Working with CLEIO allowed us to quickly show investors a certified, effective, well-designed, and attractive ready-to-market medical device that addresses critical human factors in a hospital environment. We’re moving forward with additional certification and collaborating with CLEIO’s team on the next phase of development.
François Lellouche MD,PhD
OxyNov Cofounder
Want your innovative ideas to create a positive impact?
Our experts got your back.
